Purple Biotech Adjusts ADS Ratio to Meet Nasdaq Listing Requirements
Event summary
- Purple Biotech plans to change its ADS ratio from 1:200 to 1:2,000 to comply with Nasdaq's $1.00 minimum bid price requirement.
- The change will take effect on March 2, 2026, effectively acting as a 1-for-10 reverse ADS split.
- ADS holders will receive 1 new ADS for every 10 existing ADSs, with no fractional ADSs issued.
- The company's ordinary shares on the Tel Aviv Stock Exchange will remain unaffected.
The big picture
Purple Biotech's ADS ratio change is a strategic move to avoid delisting from Nasdaq, reflecting broader trends in biotech companies adjusting their capital structures to meet exchange requirements. The shift highlights the importance of maintaining minimum bid prices for continued market access, particularly for clinical-stage companies reliant on investor confidence. The company's focus on immunotherapy and oncology positions it within a competitive sector where financial stability is crucial for advancing pipeline candidates.
What we're watching
- Market Reaction
- How investors will respond to the ADS ratio change and whether it successfully boosts the trading price.
- Nasdaq Compliance
- Whether the ADS ratio change will be sufficient to maintain listing on the Nasdaq Capital Market.
- Operational Impact
- The potential effects on liquidity and trading activity following the ratio adjustment.
Related topics